Go Pro
LON:DNL

Diurnal Group (DNL) Share Price, News & Analysis

Diurnal Group logo

About Diurnal Group Stock (LON:DNL)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
145,283 shs
Average Volume
483,617 shs
Market Capitalization
£46.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

Receive DNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DNL Stock News Headlines

DNL Share News Today
DNL.L Regulatory News
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
Diurnal Group PLC (DNL) - Investing.com UK
Da Nang Port Logistics JSC DNL
See More Headlines

DNL Stock Analysis - Frequently Asked Questions

Diurnal Group plc (LON:DNL) posted its earnings results on Tuesday, September, 15th. The company reported ($4.30) earnings per share for the quarter, beating analysts' consensus estimates of ($6.70) by $2.40.

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diurnal Group investors own include Active Energy Group (AEG), C3.ai (AI), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), B&M European Value Retail (BME) and Cerecor (CERC).

Company Calendar

Last Earnings
9/15/2020
Today
8/22/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:DNL
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.77
Current Ratio
5.23
Quick Ratio
4.16

Sales & Book Value

Annual Sales
£4.68 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
2.81
Book Value
GBX 12.70 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
169,720,000
Free Float
N/A
Market Cap
£46.33 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (LON:DNL) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners